Elecsys® β-Amyloid(1-42) CSF

ElectroChemiLuminescence Immunoassay (ECLIA) for the in vitro quantitative determination of β-Amyloid(1-42) in human Cerebrospinal Fluid (CSF)

β-Amyloid (1-42) peptide deposition in the brain is one of the two hallmarks of Alzheimer’s Disease (AD), besides neurofibrillary tangles. Pathological changes in the β-Amyloid metabolism are the earliest alterations during AD development. These changes are reflected by the decrease in the CSF concentrations of β-Amyloid (1-42) as well as by the increase in the brain uptake of the specific tracers on the β-Amyloid PET.1

Elecsys® β-Amyloid(1-42) CSF II (AB42 2) is an in vitro diagnostic immunoassay intended for the quantitative determination of the β-Amyloid(1-42) protein concentration in human cerebrospinal fluid (CSF).2

Elecsys® AB42 2 assay is part of the Elecsys® AD portfolio, along with Elecsys® Phospho-Tau (181P) CSF (pTau) and Elecsys® Total-Tau CSF (tTau) immunoassays.2

Elecsys® AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence.3,4

Elecsys® AD CSF assays enable timely intervention by identifying patients with MCI at risk of progression to AD.2,4

Elecsys® β-Amyloid(1-42) CSF

  1. Lewczuk, P. et al. 2015). Advances in Medical Sciences 60, 76-82
  2. Elecsys® Method Sheet: ms_08821941500V1.0, ms_08821909500V1.0, ms_08846715500V1.0, ms_08846693500V1.0,  ms_08846634500V1.0, ms_08846685500V1.0
  3. Rabinovici, G.D. et al. (2019). Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321(13), 1286-1294.
  4. Hansson, O. et al. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14(11), 1470-1481

Elecsys® β-Amyloid(1-42) CSF II

  • Testing time

    18 minutes

  • Test principle

    Two-step sandwich 

  • Calibration


  • Sample material

    Cerebrospinal Fluid (CSF)

  • Sample volume

    50 µL - cobas e 801 module and cobas e 402 module 

    30 µL - cobas e 411 analyzer and cobas e 601/602 modules

  • LoB (Limit of Blank)

    50 pg/mL

  • LoD (Limit of Detection)

    100 pg/mL

  • LoQ (Limit of Quantitation)

    150 pg/mL

  • Measuring range

    150 – 2,500 pg/mL

  • Reagent onboard-stability

    28 days - cobas e 801 module and cobas e 402 module

    16 weeks - cobas e 411 analyzer and cobas e 601/602 modules